In plain terms

The claim being assessed: Sleep-dependent glymphatic flow clears amyloid-beta and other solutes from brain interstitium, and its age-related failure causally contributes to neurodegeneration.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: Overall Γ follows the registered SC3 clinical disease link, while narrow transport SC1–SC2 retain Ε under an explicit physiological rubric-fit adaptation. Mouse disease perturbations strengthen plausibility and mapped context, but artificial proteinopathy/injury and AQP4's multiple functions restrict human inference. Independent human clinical mediation remains uncrossed. This does not erase the causal transport results or the genuine contradictory measurements.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Brain fluid transport is real and context dependent; its sleep-specific contribution to ordinary human neurodegeneration remains incompletely established.

Implications for health and treatment: Overall Γ follows the registered SC3 clinical disease link, while narrow transport SC1–SC2 retain Ε under an explicit physiological rubric-fit adaptation. Mouse disease perturbations strengthen plausibility and mapped context, but artificial proteinopathy/injury and AQP4's multiple functions restrict human inference. Independent human clinical mediation remains uncrossed. This does not erase the causal transport results or the genuine contradictory measurements.

Limits for individual care: 60 primary reports with 7 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 60 primary reports; claims: 64; verified: 64; unverified: 0. Verification is bounded attribution. Access: 7 partial-body and 53 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-12. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 2 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Brain fluid transport is real and context dependent; its sleep-specific contribution to ordinary human neurodegeneration remains incompletely established.

Deciding experiment: Prospectively register a selective adult pathway manipulation in a predefined aging/neurodegeneration setting, measure endogenous-solute production and net export with independent methods, and follow neuronal/functional trajectory. Match circadian timing, natural sleep, vascular dynamics and delivery pressure; add mediator rescue or epistasis before translating the physiological target to a human clinical trial.

Belief versus evidence: Overall Γ follows the registered SC3 clinical disease link, while narrow transport SC1–SC2 retain Ε under an explicit physiological rubric-fit adaptation. Mouse disease perturbations strengthen plausibility and mapped context, but artificial proteinopathy/injury and AQP4's multiple functions restrict human inference. Independent human clinical mediation remains uncrossed. This does not erase the causal transport results or the genuine contradictory measurements.

Best-supported rival: Compartment-specific exchange and diffusion. Pressure-controlled AQP4-independent uptake (PMID34128962), contrary small-dye clearance (PMID38741022), production-sensitive human kinetics (PMID29220873), and compartmental endogenous protein tracing (PMID42214342) distinguish the leading mixed-transport model from a uniform brain-wide sleep-clearance interpretation. The PS19 AQP4 perturbation (PMID35212707) preserves a real context-limited disease contribution.

COMPETING MECHANISTIC MODELS

Rank 1: Compartment-specific exchange and diffusion (Ε). Perivascular advection combines with local diffusion and route-specific efflux. Particle tracking, diffusion/pressure controls and endogenous protein tracing distinguish anatomical compartments. No single preparation measures every endogenous clearance route or explains all sleep and disease differences.

Rank 2: Parallel vascular and lymphatic drainage (Ε). Several exit routes and vascular mechanics shape solute export. Lymphatic manipulations alter restricted mouse pathology and tracing finds regional exit preferences. Parallel routes do not by themselves exclude an AQP4-linked contribution.

Rank 3: Sleep-dependent glymphatic disease contribution (Γ). Sleep-active AQP4-associated transport protects aging brains from neurodegeneration. Sleep/tracer and AQP4 disease-model interventions provide a substantial causal steelman. Human disease mediation, uniform sleep-clearance direction and exclusive parenchymal convection remain unresolved.

Rank 4: Bidirectional degeneration and fluid dysfunction (Ε). Disease and vascular/sleep disruption can impair transport that also amplifies pathology. Disease-related retention, age-dependent model responses and context reversals support feedback. Reverse-direction effects do not make all clearance impairment a passive consequence.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Sleep-dependent glymphatic flow clears amyloid-beta and other solutes from brain interstitium, and its age-related failure causally contributes to neurodegeneration.

SC3 is the causal claim at the registered human/disease or endogenous scope; narrower physiology, model interventions and associations are reported separately. Primary-subclaim aggregation is fixed before new grading.

Selection: remaining-priority list position 11 from the editorial list of 2026-10-09. Registered claim assessed against original sources. Any carried-forward edition and prior visibility are recorded in the change record; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: 01-neurodegeneration governs the disease claim. SC1 and SC2 are physiological transport components, so the endogenous perturbation definition is explicitly applied to their stated transport phenotype; this is a documented fit adaptation, not clinical disease modification. SC3 retains the rubric's disease-trajectory requirement. No revised rubric or blanket physiological-to-clinical grade transfer is used.

Foundational tracer/knockout studies establish real transport, while later pressure controls and neuropil experiments challenge universal parenchymal convection. The positive multicentre paper includes new experiments plus meta-analysis; only its original experimental component earns primary credit. PMID22896675; PMID30561329; PMID28826498; PMID34128962; PMID30451853.

Sleep findings depend on readout and state. Miao's small-dye study finds reduced net clearance, not reduced diffusion. Hauglund's 2025 original experiment includes a separate efflux assay whose association tracks NE-linked microarchitecture, not total NREM time. Its zolpidem comparison measures decreased tracer influx. Neither result supplies a human dementia treatment claim. PMID38741022; PMID39788123.

Original human kinetics identifies production as a contributor to increased amyloid during deprivation. The 2026 two-site crossover paper models device/plasma relationships, but its body states overall overnight changes did not significantly differ between conditions and tests were unadjusted for multiplicity. Its abstract says 39 participants while its measured-biomarker Results describes 38; analyzed sets and missing/QC data require care. Model agreement is not direct observation of net parenchymal export. PMID29220873; PMID41593094.

The localization study includes genuine Snta1-loss effects but also null M1/M23 overexpression, regional/time-dependent influx and a nonsignificant insoluble amyloid-42 comparison. PS19/AQP4 loss worsens neuronal loss within mutant-tau disease; non-PS19 AQP4-null controls lack that atrophy. These boundaries preserve causality in models while blocking unqualified human transfer. PMID35473943; PMID35212707; PMID42471719.

Endogenous neuronal protein tracing reveals regional exits and disease-related retention. Its authors retain limitations: mice, an exogenous tetrameric reporter, potential extra-CNS transduction, and decay reflecting both degradation and efflux. The clinical cohort evidence relates sleep and proxy signals to disease but does not isolate the proposed causal chain. PMID42214342; PMID37902739; PMID42222915; PMID39185685.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Γ follows the registered SC3 clinical disease link, while narrow transport SC1–SC2 retain Ε under an explicit physiological rubric-fit adaptation. Mouse disease perturbations strengthen plausibility and mapped context, but artificial proteinopathy/injury and AQP4's multiple functions restrict human inference. Independent human clinical mediation remains uncrossed. This does not erase the causal transport results or the genuine contradictory measurements. Sensitivities: weakest-link Γ; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] Aqp4 deletion reduces interstitial tracer and soluble amyloid clearance in mice. Tracer injection and water-channel pleiotropy do not establish human clinical mediation or universal parenchymal convection.

[3] Small-dye clearance is reduced during sleep/anesthesia while diffusion coefficients are unchanged. Male mice and small dyes; local bidirectional flow and larger-molecule differences are not excluded; correction repairs one Fig. 3b source-data column; amended raw data have not been independently reanalyzed.

[4] NE-driven vasomotion changes CSF influx; tracer efflux correlates with oscillatory microarchitecture rather than total NREM time. Zolpidem experiment measures reduced influx; it is not a human net-clearance or dementia-outcome test.

[5] Size-dependent diffusion and AQP4-independent parenchymal solute transport challenge the original bulk-flow mechanism. Does not deny convection in larger perivascular spaces; tracer-delivery context differs from positive laboratories.

[6] New experiments from five groups find reduced tracer influx in multiple Aqp4 and Snta1 knockout lines. Only original experiments count here, not the embedded meta-analysis; delivery and anesthesia remain shared assumptions.

[13] Aqp4 loss accelerates tau pathology and neuronal loss in PS19 mice. No comparable atrophy in AQP4-null non-PS19 controls; mutant-tau overexpression and lifelong water-homeostasis effects limit ordinary aging inference.

[18] Crossover sleep studies support a model relating device physiology to plasma amyloid/tau dynamics. Original body reports no significant overall sleep-vs-deprivation biomarker-change difference, unadjusted multiple tests and model/device assumptions; no disease-modifying endpoint.

[19] Neuronal protein tracing reveals compartmental border routes and disease-related retention or leakage. Reporter includes exogenous tetrameric protein; decay combines degradation and efflux; mouse routes require primate validation.

Tally: 6 positive qualifying study units across scoped subclaims; 42 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Reports sharing participants, models or instruments are not independent causal lines. Pivotal nulls do not earn positive threshold crossings.

Cap audit, precedence and Β/Γ/Δ boundary

Positive AQP4 and sleep-related physiological perturbations cross within the tested transport context. Their conditional Ε does not license ordinary-human disease contribution. Transgenic proteinopathy and seeded injury models are restricted for human inference by the ectopic/forced-model caps; human proxy/device and biomarker-only comparisons are limited by cap 4. Negative controls affect generalization, not a blanket cancellation of positive narrow transport.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Positive restricted experiments retain their experimental scope; associations and proxy movement do not establish the complete clinical claim.

SC3 cap: “Biomarker change without functional/phenotypic change caps at Γ.” AQP4 and drainage perturbations modify pathology and function in restricted injury or transgenic disease models. Those findings supply mechanistic support, but ordinary-human age-related degeneration is not selectively mediated by an independently validated glymphatic intervention with clinical trajectory. Human kinetic/proxy studies and an overall-null biomarker-change comparison cannot cross that clinical boundary.

SC1 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. AQP4-linked transport and perivascular pumping have positive endogenous perturbation support in defined mouse preparations. Solute size, localization and pressure matter, and constant-pressure and diffusion experiments provide genuine contrary results. Context-specific transport is established; uniform brain-wide parenchymal bulk convection is not.

SC2 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. State-related clearance has causal support within defined tracer and rodent sleep preparations, while the small human gadobutrol intervention is supportive. The direction is not universal across methods or solutes: Miao's small-dye clearance decreases in sleep, and Hauglund's efflux result tracks microarchitecture rather than total NREM duration. Human plasma/device modeling and pulsations alone do not establish net endogenous-solute export.

SC3 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. AQP4 and drainage perturbations modify pathology and function in restricted injury or transgenic disease models. Those findings supply mechanistic support, but ordinary-human age-related degeneration is not selectively mediated by an independently validated glymphatic intervention with clinical trajectory. Human kinetic/proxy studies and an overall-null biomarker-change comparison cannot cross that clinical boundary.

Upward threshold ladder

SC1 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes.

SC1 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes.

SC1 Ζ: “Requires: - Multiple independent causal lines in vivo - Replication across at least two relevant systems - Narrowing of major alternative models” Satisfied: no. Independent laboratories need a pressure-controlled, compartment-resolved mass balance with endogenous-solute kinetics and selective adult AQP4/localization perturbation; reproduce both influx and efflux while excluding geometry and water-homeostasis alternatives.

SC2 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes.

SC2 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes.

SC2 Ζ: “Requires: - Multiple independent causal lines in vivo - Replication across at least two relevant systems - Narrowing of major alternative models” Satisfied: no. Replicate state-dependent net endogenous-solute export across methods and species, with matched tracer delivery, production/degradation, circadian time and vascular dynamics; explain the opposing small-dye result rather than discard it.

SC3 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. A prospectively registered target-engaged human manipulation must change an objectively measured neurodegenerative trajectory, with independent clearance-rate and production measurements and mediation controls. A proxy/device or plasma biomarker change alone is insufficient.

Upper ladder: Human randomized sleep opportunity, kinetics, longitudinal sleep/dementia cohorts and AQP4/ALPS genetic data were considered. They constrain different errors but do not establish a validated clearance-specific human clinical causal instrument. ALPS genetics is genetics of a proxy. No assembled same-scope clinical causal set is downgraded merely because one component is observational. Necessity and sufficiency of a uniform route are not established.

Independence: Related mouse laboratories, Aqp4/Snta1 lines and tracer protocols are not automatically independent causal lines. Human CSF kinetic papers share measurement traditions; Framingham reports share a cohort, and ADNI proxy papers share resource/assay failure modes. Cross-method disagreements are retained. The two-site human device analysis shares its sponsor/instrument/model and is not two independent mechanism-identification lines.

Mouse endogenous transport perturbations [1, 6, 38]: Reduce a purely observational transport explanation but share tracer/preparation and constitutive-knockout assumptions.

Orthogonal direct transport challenges [5, 20, 3]: Probe diffusion and delivery-pressure assumptions; differing preparations must be matched before comparing effects.

Human physiology and kinetics [9, 17, 18]: Reduce mouse-only dependence, but small clinical samples, distinct solutes and model/device assumptions limit pathway specificity.

Restricted disease perturbations [13, 39, 40]: Change pathology/function in models, with shared artificial proteinopathy and pleiotropy still present.

Falsification and pitfalls

Method- and context-dependent contrary results. Direct diffusion/AQP4-null and small-dye sleep tests oppose a uniform-convection prediction; scope is not rescued by selecting successful protocols after outcomes. Additional downgrade: False.

Influx treated as clearance. CSF tracer enrichment and impedance/ALPS proxies do not alone identify net export.

Model-to-human transfer. Artificial proteinopathy, injury and rodent drug effects retain scope limits.

Production-release conflated with export. Sleep-dependent amyloid/tau concentrations combine several processes.

Adversarial steelman: above, then below

One rung above, Δ: selective AQP4-related interventions change mouse pathological and functional trajectories, making a real contribution plausible. But SC3 asks for age-related neurodegeneration at the human disease scope, and the physiology/proxy trials do not isolate that mediator against disease progression. Transfer from artificial proteinopathy or acute injury is still restricted.

One rung below, Β: human clinical evidence is largely association and indirect measurement. Yet mouse endogenous transport perturbation, functional model effects and direct physiological comparisons supply support beyond association. Γ preserves that mechanistic content while retaining contradictions.

Retain Γ at SC3; narrower physiological effects remain Ε. Neither the nominal model nor its rivals acquire human clinical causality from tracer access or model fit alone.

Final score, causal direction and M/S/D

Overall Γ follows the registered SC3 clinical disease link, while narrow transport SC1–SC2 retain Ε under an explicit physiological rubric-fit adaptation. Mouse disease perturbations strengthen plausibility and mapped context, but artificial proteinopathy/injury and AQP4's multiple functions restrict human inference. Independent human clinical mediation remains uncrossed. This does not erase the causal transport results or the genuine contradictory measurements.

Disease-model perturbations exclude a solely passive downstream interpretation in those contexts. Clearance impairment can amplify protein accumulation and neuronal damage, while disease can itself obstruct exit routes. Ordinary-human initiation, removal preventing degeneration and rate limitation are not jointly shown, nor universal necessity. Step 5 supports a restricted amplifier/maintenance contribution rather than a universal initiating driver.

Momentum: Mechanistic only. The 2025 NE/vasomotion perturbations (PMID39788123), 2026 neuronal tracing (PMID42214342) and AQP4 epistasis in PS19 (PMID42471719) test mechanism and context. They do not complete a clearance-specific human neurodegeneration trial.

Stability: Stable. No verified named pending result was identified that demonstrably determines the full-scope letter; this is a bounded search finding, not proof that none exists.

Divergence: Contested. The field is genuinely split rather than uniformly overstating: the originating laboratories and much review and press framing present sleep-dependent glymphatic clearance as an established determinant of neurodegeneration, while the pressure-controlled, diffusion and small-dye literature presents the parenchymal convection step as unsettled, so no single implied level and no single rung arithmetic applies. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Prospectively register a selective adult pathway manipulation in a predefined aging/neurodegeneration setting, measure endogenous-solute production and net export with independent methods, and follow neuronal/functional trajectory. Match circadian timing, natural sleep, vascular dynamics and delivery pressure; add mediator rescue or epistasis before translating the physiological target to a human clinical trial.

Readout: Compartment-resolved clearance rate, production/degradation and prespecified disease/function trajectory. Controls: Pressure and injection trauma, solute size, EEG state, sleep microarchitecture, vascular/autonomic effects, water homeostasis, model genotype and independent analysis. Supporting: Selective engagement improves verified export and durable trajectory with mediation and independent replication. Falsifying: Target engagement changes tracer entry or device signal without net export or functional benefit, or production/parallel exits explain the apparent effect.

KNOWLEDGE GAPS

Influx, redistribution, degradation and net export need independent mass-balance measurements.

Opposite sleep results require matched injection recovery, solute size, compartment and physiological state.

AQP4 affects water homeostasis and cell function beyond the proposed route.

Human device/model estimates need held-out orthogonal clearance validation; plasma changes alone do not identify the route.

A clearance-specific human disease-trajectory intervention and directionally valid genetic instrument remain unverified.

REVIEWER NOTES

Original primary abstracts/status records and selected body passages were examined. Most full papers and supplements were not audited. Consensus browser synthesis supplements discovery and original-source reconciliation. No independent blinded grading or scientific peer review is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Consensus did not retrieve Miao's original study. Its examined original Results show lower small-dye net clearance during sleep or anesthesia with unchanged diffusion coefficients. This is contrary evidence for a uniform sleep-clearance prediction, with male-mouse, solute-size and preparation limits. The publisher correction repairs one source-data column; amended raw data have not been reanalyzed. Original PMID38741022.

Consensus selected a 2025 review rather than the original Cell experiment. The original body separates an efflux assay from influx, finds associations with noradrenergic microarchitecture rather than total NREM duration, and reports zolpidem-reduced tracer influx. It does not establish that zolpidem causes human dementia. Original PMID39788123.

The original 2026 body reports no significant overall between-condition difference in overnight plasma biomarker changes, despite modeled physiological associations. Its abstract and measured-biomarker Results use different participant counts. An impedance/compartment estimate is not direct observation of net parenchymal export or a dementia-prevention outcome. Original PMID41593094.

Original human isotope kinetics attributes a deprivation-related amyloid increase to increased production, while fractional turnover and delay comparisons are nonsignificant. A concentration rise alone cannot validate reduced glymphatic clearance. Original PMID29220873.

The examined original report supports diffusion-based parenchymal movement and AQP4-independent transport in its preparation. It supplies an actual mechanistic contrast; differences in tracer delivery and compartments must be reconciled rather than dismissing one preparation. Original PMID28826498.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Glymphatic Clearance Hypothesis

Selected publication milestones, not an exhaustive history or discovery priority claim.

2012 — Tracer and AQP4 experiments establish a restricted perivascular transport mechanism. Original PMID22896675.

2013 — Sleep-state experiments associate larger interstitial space with increased clearance in mice. Original PMID24136970.

2017 — Direct diffusion and AQP4-independent measurements challenge uniform parenchymal convection. Original PMID28826498.

2018 — Human isotope kinetics distinguishes amyloid production from fractional clearance. Original PMID29220873.

2022 — AQP4 loss worsens pathology in a mutant-tau mouse model. Original PMID35212707.

2024 — Small-dye experiments report reduced clearance during sleep and anesthesia. Original PMID38741022.

2025 — Noradrenergic oscillations link sleep microarchitecture to fluid transport. Original PMID39788123.

2026 — Endogenous neuronal protein tracing resolves compartment-specific exit routes. Original PMID42214342.

Research gaps

Influx, redistribution, degradation and net export need independent mass-balance measurements.

Opposite sleep results require matched injection recovery, solute size, compartment and physiological state.

AQP4 affects water homeostasis and cell function beyond the proposed route.

Human device/model estimates need held-out orthogonal clearance validation; plasma changes alone do not identify the route.

A clearance-specific human disease-trajectory intervention and directionally valid genetic instrument remain unverified.

Boundary experiment

Prospectively register a selective adult pathway manipulation in a predefined aging/neurodegeneration setting, measure endogenous-solute production and net export with independent methods, and follow neuronal/functional trajectory. Match circadian timing, natural sleep, vascular dynamics and delivery pressure; add mediator rescue or epistasis before translating the physiological target to a human clinical trial.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. All 60 REFERENCES PMIDs were verified against PubMed metadata for first author, title, journal and year; 60/60 resolve to the stated record, with no wrong identifier, retraction or expression of concern. The five linked notices were checked individually: PMID 38877307 is the Author Correction to the Miao small-dye paper, PMID 37905872, 39351889 and 41253750 are Published Errata on their parent records, and PMID 37034667 is the bioRxiv predecessor recorded as "Update of" the peer-reviewed gBOLD-CSF paper — so no level rests on non-peer-reviewed work and sources_total is not inflated by notices. Ten load-bearing claims were spot-checked: Iliff (22896675) AQP4 deletion with roughly 70% reduction in interstitial solute clearance and suppressed soluble amyloid-β clearance; Smith (34128962) constant-pressure application showing AQP4-independent parenchymal uptake with no wild-type versus knockout difference; Miao (38741022) clearance reduced during sleep and anesthesia in male mice with movement independent of state; Hauglund (39788123) norepinephrine-linked slow vasomotion as the strongest predictor of NREM clearance, arterial-oscillation stimulation enhancing CSF inflow, and zolpidem suppressing norepinephrine oscillations and flow; Mestre (30561329) multicentre new experiments plus meta-analysis, of which only the experimental component is credited here; Lucey (29220873) human overnight kinetics with production as a contributor; the PS19 AQP4 perturbation (35212707) with no comparable atrophy in AQP4-null non-PS19 controls; the localisation study (35473943) with Snta1-loss effects alongside null M1/M23 overexpression; the 2026 two-site crossover (41593094), where the review's reading of the body — no significant overall difference in overnight biomarker change between conditions, unadjusted multiple tests, and an abstract-versus-Results participant count of 39 against 38 — is a full-text-level check the ledger's full_text_partial depth supports; and the endogenous neuronal protein tracing (42214342) with its authors' own limitations retained. All ten were accurately attributed for direction of effect, species, sex, solute size and design, including the distinction between influx and net clearance that most of this literature turns on. Scoring logic was re-derived: primary-subclaim aggregation on SC3 is applied as written, and here all three rules return Γ (weakest-link Γ, primary-subclaim Γ, scope-matched Γ) because SC3's scope is the registered claim's scope; the narrower Ε transport subclaims are reported separately rather than promoted; cap 4 is applied to the human proxy, device and biomarker-only comparisons and the forced-model caps to the transgenic and injury work.

Findings

Rejected findings (checked, no change)

1. Γ while SC1 and SC2 sit at Ε. Checked against the aggregation rule and against the alternatives. All three rules return Γ because SC3's scope is the registered claim's scope; the transport subclaims are narrower and are reported separately, which is what the rule requires. No scope-matched misreading.
2. Ε for SC1 and SC2 rather than Δ or Ζ. Argued both ways. Ζ fails because the mouse transport lines share tracer delivery, preparation and constitutive-knockout assumptions, and the review says so; Δ would understate genuinely positive endogenous perturbations in defined preparations. The explicit rubric-fit adaptation — applying the endogenous-perturbation definition to a transport phenotype rather than to disease modification — is documented as an adaptation rather than used silently, which is what the framework requires.
3. Momentum "Mechanistic only". The artifact names three specific 2025-2026 experimental programmes and states what they do not do. Correctly refuses "Decisive work underway" in the absence of a clearance-specific human trial.
4. Stability "Stable". No named pending result was verified, and the review says this is a bounded search finding rather than proof that none exists. That is what "Stable" means in the framework.
5. Causal role "reinforcing / stabilizing factor". Primary driver fails the derivation because removal does not prevent ordinary human neurodegeneration and the pathway is not shown to be rate-limiting; downstream consequence fails because the model perturbations do change pathology. Step 5 is correct.
6. The Hauglund zolpidem reading. The abstract says zolpidem suppressed "glymphatic flow"; the review narrows this to decreased tracer influx. Checked: the ledger records full_text_partial for this source, and narrowing an abstract's summary term to the quantity actually measured is the opposite of overclaiming. No change.
7. The 39-versus-38 participant discrepancy in PMID 41593094. Reported as a feature of the source, not asserted as the review's own count, and flagged alongside the unadjusted multiplicity. Correct handling of a source-internal inconsistency.
8. Citation-year differences of one year from PubMed e-pub dates, and PubMed titles dropping Greek letters. House convention. No collective-author rendering defect is present in this reference list.
9. The "Best-supported rival" field. Checked against the score card for the renderer defect that prints models_evaluated[0]: here that entry is the rank-1 non-nominal model (is_nominal: false) and the nominal sits lower in the tournament, so the prose is correct. No change.
10. Confidence band Moderate. Verified against the framework's confidence text rather than against the reviewer's access depth. Moderate is correct: the literature contains outright opposing results across tracer-delivery and pressure conditions, so High's well-established reproducibility is not met. The band is correct, although the score card's confidence_rationale boilerplate also mentions incomplete access.
11. Provenance and approval clauses. No earlier adversarial approval is asserted anywhere in this document, and the REVIEWER NOTES provenance statements match what this case actually did, including its use of Consensus. No change.

Residual limitations

Seven of 60 sources were examined beyond abstract depth, so most numerical claims rest on abstracts. The amended raw data behind the Miao correction have not been independently reanalysed here, as the review itself notes. The central disagreement in this field is between laboratories using different tracer-delivery and pressure conditions, and no examined source performs the matched comparison that would settle it; the Γ therefore reflects an unresolved methodological dispute as much as a missing clinical experiment.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Iliff JJ, Wang M, Liao Y et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Science translational medicine. 2012. PMID 22896675. DOI: 10.1126/scitranslmed.3003748. Access: abstract_metadata. Study: PMID22896675.

2. Xie L, Kang H, Xu Q et al. Sleep drives metabolite clearance from the adult brain. Science (New York, N.Y.). 2013. PMID 24136970. DOI: 10.1126/science.1241224. Access: abstract_metadata. Study: PMID24136970.

3. Miao A, Luo T, Hsieh B et al. Brain clearance is reduced during sleep and anesthesia. Nature neuroscience. 2024. PMID 38741022. DOI: 10.1038/s41593-024-01638-y. Access: full_text_partial. Study: PMID38741022.

4. Hauglund NL, Andersen M, Tokarska K et al. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell. 2025. PMID 39788123. DOI: 10.1016/j.cell.2024.11.027. Access: full_text_partial. Study: PMID39788123.

5. Smith AJ, Yao X, Dix JA et al. Test of the 'glymphatic' hypothesis demonstrates diffusive and aquaporin-4-independent solute transport in rodent brain parenchyma. eLife. 2017. PMID 28826498. DOI: 10.7554/eLife.27679. Access: abstract_metadata. Study: PMID28826498.

6. Mestre H, Hablitz LM, Xavier AL et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. eLife. 2018. PMID 30561329. DOI: 10.7554/eLife.40070. Access: abstract_metadata. Study: PMID30561329.

7. Mestre H, Tithof J, Du T et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nature communications. 2018. PMID 30451853. DOI: 10.1038/s41467-018-07318-3. Access: abstract_metadata. Study: PMID30451853.

8. Fultz NE, Bonmassar G, Setsompop K et al. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science (New York, N.Y.). 2019. PMID 31672896. DOI: 10.1126/science.aax5440. Access: abstract_metadata. Study: PMID31672896.

9. Lucey BP, Hicks TJ, McLeland JS et al. Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. Annals of neurology. 2018. PMID 29220873. DOI: 10.1002/ana.25117. Access: full_text_partial. Study: PMID29220873.

10. Holth JK, Fritschi SK, Wang C et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science (New York, N.Y.). 2019. PMID 30679382. DOI: 10.1126/science.aav2546. Access: abstract_metadata. Study: PMID30679382.

11. Kress BT, Iliff JJ, Xia M et al. Impairment of paravascular clearance pathways in the aging brain. Annals of neurology. 2014. PMID 25204284. DOI: 10.1002/ana.24271. Access: abstract_metadata. Study: PMID25204284.

12. Simon M, Wang MX, Ismail O et al. Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice. Alzheimer's research & therapy. 2022. PMID 35473943. DOI: 10.1186/s13195-022-00999-5. Access: full_text_partial. Study: PMID35473943.

13. Ishida K, Yamada K, Nishiyama R et al. Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. The Journal of experimental medicine. 2022. PMID 35212707. DOI: 10.1084/jem.20211275. Access: full_text_partial. Study: PMID35212707.

14. Harrison IF, Ismail O, Machhada A et al. Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. Brain : a journal of neurology. 2020. PMID 32705145. DOI: 10.1093/brain/awaa179. Access: abstract_metadata. Study: PMID32705145.

15. Iliff JJ, Chen MJ, Plog BA et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2014. PMID 25471560. DOI: 10.1523/JNEUROSCI.3020-14.2014. Access: abstract_metadata. Study: PMID25471560.

16. Murdock MH, Yang CY, Sun N et al. Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature. 2024. PMID 38418876. DOI: 10.1038/s41586-024-07132-6. Access: abstract_metadata. Study: PMID38418876.

17. Eide PK, Vinje V, Pripp AH et al. Sleep deprivation impairs molecular clearance from the human brain. Brain : a journal of neurology. 2021. PMID 33829232. DOI: 10.1093/brain/awaa443. Access: abstract_metadata. Study: PMID33829232.

18. Dagum P, Elbert DL, Giovangrandi L et al. The glymphatic system clears amyloid beta and tau from brain to plasma in humans. Nature communications. 2026. PMID 41593094. DOI: 10.1038/s41467-026-68374-8. Access: full_text_partial. Study: PMID41593094.

19. Chayama Y, Rao NR, Perla D et al. Physiological brain clearance architecture revealed by neuronal protein tracing. Cell. 2026. PMID 42214342. DOI: 10.1016/j.cell.2026.04.048. Access: full_text_partial. Study: PMID42214342.

20. Smith AJ, Akdemir G, Wadhwa M et al. Application of fluorescent dextrans to the brain surface under constant pressure reveals AQP4-independent solute uptake. The Journal of general physiology. 2021. PMID 34128962. DOI: 10.1085/jgp.202112898. Access: abstract_metadata. Study: PMID34128962.

21. Holter KE, Kehlet B, Devor A et al. Interstitial solute transport in 3D reconstructed neuropil occurs by diffusion rather than bulk flow. Proceedings of the National Academy of Sciences of the United States of America. 2017. PMID 28847942. DOI: 10.1073/pnas.1706942114. Access: abstract_metadata. Study: PMID28847942.

22. Lee H, Xie L, Yu M et al. The Effect of Body Posture on Brain Glymphatic Transport. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015. PMID 26245965. DOI: 10.1523/JNEUROSCI.1625-15.2015. Access: abstract_metadata. Study: PMID26245965.

23. Hablitz LM, Plá V, Giannetto M et al. Circadian control of brain glymphatic and lymphatic fluid flow. Nature communications. 2020. PMID 32879313. DOI: 10.1038/s41467-020-18115-2. Access: abstract_metadata. Study: PMID32879313.

24. Lundgaard I, Lu ML, Yang E et al. Glymphatic clearance controls state-dependent changes in brain lactate concentration. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2017. PMID 27481936. DOI: 10.1177/0271678X16661202. Access: abstract_metadata. Study: PMID27481936.

25. Zeppenfeld DM, Simon M, Haswell JD et al. Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. JAMA neurology. 2017. PMID 27893874. DOI: 10.1001/jamaneurol.2016.4370. Access: abstract_metadata. Study: PMID27893874.

26. Shokri-Kojori E, Wang GJ, Wiers CE et al. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proceedings of the National Academy of Sciences of the United States of America. 2018. PMID 29632177. DOI: 10.1073/pnas.1721694115. Access: abstract_metadata. Study: PMID29632177.

27. Himali JJ, Baril AA, Cavuoto MG et al. Association Between Slow-Wave Sleep Loss and Incident Dementia. JAMA neurology. 2023. PMID 37902739. DOI: 10.1001/jamaneurol.2023.3889. Access: abstract_metadata. Study: PMID37902739.

28. Han F, Chen J, Belkin-Rosen A et al. Reduced coupling between cerebrospinal fluid flow and global brain activity is linked to Alzheimer disease-related pathology. PLoS biology. 2021. PMID 34061820. DOI: 10.1371/journal.pbio.3001233. Access: abstract_metadata. Study: PMID34061820.

29. Picchioni D, Özbay PS, Mandelkow H et al. Autonomic arousals contribute to brain fluid pulsations during sleep. NeuroImage. 2022. PMID 35017126. DOI: 10.1016/j.neuroimage.2022.118888. Access: abstract_metadata. Study: PMID35017126.

30. Helakari H, Korhonen V, Holst SC et al. Human NREM Sleep Promotes Brain-Wide Vasomotor and Respiratory Pulsations. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2022. PMID 35135852. DOI: 10.1523/JNEUROSCI.0934-21.2022. Access: abstract_metadata. Study: PMID35135852.

31. Tuura RO, Volk C, Callaghan F et al. Sleep-related and diurnal effects on brain diffusivity and cerebrospinal fluid flow. NeuroImage. 2021. PMID 34302966. DOI: 10.1016/j.neuroimage.2021.118420. Access: abstract_metadata. Study: PMID34302966.

32. Eide PK, Pripp AH, Berge B et al. Altered glymphatic enhancement of cerebrospinal fluid tracer in individuals with chronic poor sleep quality. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2022. PMID 35350917. DOI: 10.1177/0271678X221090747. Access: abstract_metadata. Study: PMID35350917.

33. Huang Y, Potter R, Sigurdson W et al. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Archives of neurology. 2012. PMID 21911660. DOI: 10.1001/archneurol.2011.235. Access: abstract_metadata. Study: PMID21911660.

34. Lucey BP, Mawuenyega KG, Patterson BW et al. Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System. JAMA neurology. 2017. PMID 27992627. DOI: 10.1001/jamaneurol.2016.4202. Access: abstract_metadata. Study: PMID27992627.

35. Han F, Liu X, Yang Y et al. Sex-specific age-related differences in cerebrospinal fluid clearance assessed by resting-state functional magnetic resonance imaging. NeuroImage. 2024. PMID 39461604. DOI: 10.1016/j.neuroimage.2024.120905. Access: abstract_metadata. Study: PMID39461604.

36. Boespflug EL, Simon MJ, Leonard E et al. Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2018. PMID 30475760. DOI: 10.3233/JAD-180367. Access: abstract_metadata. Study: PMID30475760.

37. Huang SY, Ge YJ, Ren P et al. Genome-wide association study unravels mechanisms of brain glymphatic activity. Nature communications. 2025. PMID 39805841. DOI: 10.1038/s41467-024-55706-9. Access: abstract_metadata. Study: PMID39805841.

38. Bojarskaite L, Nafari S, Ravnanger AK et al. Role of aquaporin-4 polarization in extracellular solute clearance. Fluids and barriers of the CNS. 2024. PMID 38532513. DOI: 10.1186/s12987-024-00527-7. Access: abstract_metadata. Study: PMID38532513.

39. Yamada K, Ishida K, Sakamoto A et al. AQP4-dependent enhancement of glymphatic function attenuates tau pathology and neurodegeneration in PS19 mice. Molecular neurodegeneration. 2026. PMID 42471719. DOI: 10.1186/s13024-026-00977-7. Access: abstract_metadata. Study: PMID42471719.

40. Chen K, Morizawa YM, Nuriel T et al. Selective removal of astrocytic PERK protects against glymphatic impairment and decreases toxic aggregation of β-amyloid and tau. Neuron. 2025. PMID 40403715. DOI: 10.1016/j.neuron.2025.04.027. Access: abstract_metadata. Study: PMID40403715.

41. Wang M, Yan C, Li X et al. Non-invasive modulation of meningeal lymphatics ameliorates ageing and Alzheimer's disease-associated pathology and cognition in mice. Nature communications. 2024. PMID 38365740. DOI: 10.1038/s41467-024-45656-7. Access: abstract_metadata. Study: PMID38365740.

42. Wang L, Zhang Y, Zhao Y et al. Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice. Brain pathology (Zurich, Switzerland). 2019. PMID 30192999. DOI: 10.1111/bpa.12656. Access: abstract_metadata. Study: PMID30192999.

43. Cao X, Xu H, Feng W et al. Deletion of aquaporin-4 aggravates brain pathology after blocking of the meningeal lymphatic drainage. Brain research bulletin. 2018. PMID 30347264. DOI: 10.1016/j.brainresbull.2018.10.007. Access: abstract_metadata. Study: PMID30347264.

44. Jong Huat T, Camats-Perna J, Newcombe EA et al. The impact of astrocytic NF-κB on healthy and Alzheimer's disease brains. Scientific reports. 2024. PMID 38906984. DOI: 10.1038/s41598-024-65248-1. Access: abstract_metadata. Study: PMID38906984.

45. Palatsides EL, Yiallourou S, Himali D et al. Influence of an AQP4 haplotype and sleep duration on early Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID 42222915. DOI: 10.1002/alz.71540. Access: abstract_metadata. Study: PMID42222915.

46. Eide PK, Lashkarivand A, Pripp A et al. Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders. Nature communications. 2023. PMID 37045847. DOI: 10.1038/s41467-023-37685-5. Access: abstract_metadata. Study: PMID37045847.

47. Liu Y, Hu PP, Zhai S et al. Aquaporin 4 deficiency eliminates the beneficial effects of voluntary exercise in a mouse model of Alzheimer's disease. Neural regeneration research. 2022. PMID 35142700. DOI: 10.4103/1673-5374.335169. Access: abstract_metadata. Study: PMID35142700.

48. Liu G, Mestre H, Sweeney AM et al. Direct Measurement of Cerebrospinal Fluid Production in Mice. Cell reports. 2020. PMID 33357428. DOI: 10.1016/j.celrep.2020.108524. Access: abstract_metadata. Study: PMID33357428.

49. Vindedal GF, Thoren AE, Jensen V et al. Removal of aquaporin-4 from glial and ependymal membranes causes brain water accumulation. Molecular and cellular neurosciences. 2016. PMID 27751903. DOI: 10.1016/j.mcn.2016.10.004. Access: abstract_metadata. Study: PMID27751903.

50. Munk AS, Wang W, Bèchet NB et al. PDGF-B Is Required for Development of the Glymphatic System. Cell reports. 2019. PMID 30865886. DOI: 10.1016/j.celrep.2019.02.050. Access: abstract_metadata. Study: PMID30865886.

51. Plog BA, Dashnaw ML, Hitomi E et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015. PMID 25589747. DOI: 10.1523/JNEUROSCI.3742-14.2015. Access: abstract_metadata. Study: PMID25589747.

52. Mestre H, Du T, Sweeney AM et al. Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science (New York, N.Y.). 2020. PMID 32001524. DOI: 10.1126/science.aax7171. Access: abstract_metadata. Study: PMID32001524.

53. Wu CH, Liao WH, Chu YC et al. Very Low-Intensity Ultrasound Facilitates Glymphatic Influx and Clearance via Modulation of the TRPV4-AQP4 Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024. PMID 39494466. DOI: 10.1002/advs.202401039. Access: abstract_metadata. Study: PMID39494466.

54. Zimmermann J, Sorg C, Müller L et al. Impaired Macroscopic Cerebrospinal Fluid Flow by Sevoflurane in Humans during and after Anesthesia. Anesthesiology. 2025. PMID 39786916. DOI: 10.1097/ALN.0000000000005360. Access: abstract_metadata. Study: PMID39786916.

55. Wu W, Zhao Y, Cheng X et al. Modulation of glymphatic system by visual circuit activation alleviates memory impairment and apathy in a mouse model of Alzheimer's disease. Nature communications. 2025. PMID 39747869. DOI: 10.1038/s41467-024-55678-w. Access: abstract_metadata. Study: PMID39747869.

56. Sun X, Dias L, Peng C et al. 40 Hz light flickering facilitates the glymphatic flow via adenosine signaling in mice. Cell discovery. 2024. PMID 39103336. DOI: 10.1038/s41421-024-00701-z. Access: abstract_metadata. Study: PMID39103336.

57. Sun H, Cao Q, He X et al. Melatonin Mitigates Sleep Restriction-Induced Cognitive and Glymphatic Dysfunction Via Aquaporin-4 Polarization. Molecular neurobiology. 2025. PMID 40293704. DOI: 10.1007/s12035-025-04992-5. Access: abstract_metadata. Study: PMID40293704.

58. Sun YR, Lv QK, Xue XY et al. Sleep deprivation accelerates Parkinson's disease pathology by upregulating LAG3 in astrocytes and disrupting glymphatic system function. Journal of advanced research. 2026. PMID 41980625. DOI: 10.1016/j.jare.2026.04.035. Access: abstract_metadata. Study: PMID41980625.

59. Peng C, Sun X, Zhang Z et al. Chronic intermittent hypoxia impairs glymphatic function in male mice through ENT-dependent adenosine dysregulation. Sleep. 2026. PMID 42412752. DOI: 10.1093/sleep/zsag182. Access: abstract_metadata. Study: PMID42412752.

60. Sacchi L, D'Agata F, Campisi C et al. A "glympse" into neurodegeneration: Diffusion MRI and cerebrospinal fluid aquaporin-4 for the assessment of glymphatic system in Alzheimer's disease and other dementias. Human brain mapping. 2024. PMID 39185685. DOI: 10.1002/hbm.26805. Access: abstract_metadata. Study: PMID39185685.

Source-specific evidence cards

[1] A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.

Shows: Aqp4 deletion reduces interstitial tracer and soluble amyloid clearance in mice.

Does not show: Tracer injection and water-channel pleiotropy do not establish human clinical mediation or universal parenchymal convection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[2] Sleep drives metabolite clearance from the adult brain.

Shows: Natural sleep and anesthesia increase interstitial space and radiotracer amyloid clearance in mice.

Does not show: State, anesthesia and injection conditions require separate adjudication; not a disease-prevention trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[3] Brain clearance is reduced during sleep and anesthesia.

Shows: Small-dye clearance is reduced during sleep/anesthesia while diffusion coefficients are unchanged.

Does not show: Male mice and small dyes; local bidirectional flow and larger-molecule differences are not excluded; correction repairs one Fig. 3b source-data column; amended raw data have not been independently reanalyzed.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Main:paragraph8, 0:Main:paragraph12, 0:Main:paragraph16, 0:Main:paragraph17. No complete-paper or supplement audit claimed. Erratum in: PMID 38877307. Subclaims: SC1, SC2.

[4] Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep.

Shows: NE-driven vasomotion changes CSF influx; tracer efflux correlates with oscillatory microarchitecture rather than total NREM time.

Does not show: Zolpidem experiment measures reduced influx; it is not a human net-clearance or dementia-outcome test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph10, 1:Results:paragraph11, 1:Results:paragraph12, 1:Results:paragraph13. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[5] Test of the 'glymphatic' hypothesis demonstrates diffusive and aquaporin-4-independent solute transport in rodent brain parenchyma.

Shows: Size-dependent diffusion and AQP4-independent parenchymal solute transport challenge the original bulk-flow mechanism.

Does not show: Does not deny convection in larger perivascular spaces; tracer-delivery context differs from positive laboratories.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[6] Aquaporin-4-dependent glymphatic solute transport in the rodent brain.

Shows: New experiments from five groups find reduced tracer influx in multiple Aqp4 and Snta1 knockout lines.

Does not show: Only original experiments count here, not the embedded meta-analysis; delivery and anesthesia remain shared assumptions.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[7] Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension.

Shows: Particle tracking measures pulsatile perivascular CSF flow and hypertension-related backflow.

Does not show: Perivascular pumping is not proof of bulk flow throughout neuropil or clinical disease modification.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep.

Shows: Human NREM sleep couples neural slow waves, hemodynamics and macroscopic CSF oscillations.

Does not show: CSF oscillation is not measured net solute export or a dementia endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[9] Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics.

Shows: Sleep deprivation raises amyloid production without a significant change in modeled fractional turnover.

Does not show: Small physiological intervention; turnover models have assumptions and do not rule out every local transport effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph0. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[10] The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.

Shows: Wakefulness/deprivation raises extracellular tau; chronic deprivation increases spreading in a seeded model.

Does not show: Release/production and artificial seeding do not isolate glymphatic mediation or ordinary human disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[11] Impairment of paravascular clearance pathways in the aging brain.

Shows: Aging mice show impaired injected amyloid clearance with reduced pulsatility and AQP4 polarization.

Does not show: Age comparison is not selective restoration or prevention of aging-related clinical degeneration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[12] Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice.

Shows: Snta1 deletion changes tracer exchange and selected amyloid pools; human localization correlates with pathology.

Does not show: Fine-process AQP4 overexpression does not reproduce the phenotype; region, time and amyloid species include nulls.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph17, 2:Results:paragraph19, 2:Results:paragraph22, 2:Results:paragraph24, 2:Results:paragraph25. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[13] Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration.

Shows: Aqp4 loss accelerates tau pathology and neuronal loss in PS19 mice.

Does not show: No comparable atrophy in AQP4-null non-PS19 controls; mutant-tau overexpression and lifelong water-homeostasis effects limit ordinary aging inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results and discussion:paragraph6, 1:Results and discussion:paragraph11, 1:Results and discussion:paragraph16. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[14] Impaired glymphatic function and clearance of tau in an Alzheimer's disease model.

Shows: Tauopathy shows impaired exchange; TGN-020 reduces tau clearance.

Does not show: Acute inhibitor, reporter transport and transgenic pathology do not establish human disease trajectory mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[15] Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury.

Shows: TBI impairs tracer clearance; Aqp4 knockout worsens post-traumatic tau pathology and degeneration.

Does not show: Traumatic injury is a restricted context with vascular and inflammatory effects, not ordinary aging.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[16] Multisensory gamma stimulation promotes glymphatic clearance of amyloid.

Shows: Gamma stimulation promotes influx/efflux and amyloid removal with VIP-pathway manipulation in 5xFAD.

Does not show: Sensory stimulation has multiple effects; amyloid removal is not by itself a human functional endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[17] Sleep deprivation impairs molecular clearance from the human brain.

Shows: One-night deprivation in a small matched clinical cohort increases retained intrathecal gadobutrol tracer.

Does not show: Nonrandomized groups and intrathecal contrast; tracer retention does not uniquely identify AQP4 or endogenous amyloid transport.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[18] The glymphatic system clears amyloid beta and tau from brain to plasma in humans.

Shows: Crossover sleep studies support a model relating device physiology to plasma amyloid/tau dynamics.

Does not show: Original body reports no significant overall sleep-vs-deprivation biomarker-change difference, unadjusted multiple tests and model/device assumptions; no disease-modifying endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Method:paragraph9, 2:Results:paragraph0, 2:Results:paragraph1, 2:Results:paragraph18. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[19] Physiological brain clearance architecture revealed by neuronal protein tracing.

Shows: Neuronal protein tracing reveals compartmental border routes and disease-related retention or leakage.

Does not show: Reporter includes exogenous tetrameric protein; decay combines degradation and efflux; mouse routes require primate validation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Limitations of the study:paragraph0. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[20] Application of fluorescent dextrans to the brain surface under constant pressure reveals AQP4-independent solute uptake.

Shows: Constant-pressure solute application yields AQP4-independent uptake and injection-pressure effects.

Does not show: Durotomy and surface application are a distinct preparation, not definitive whole-brain physiological efflux measurement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[21] Interstitial solute transport in 3D reconstructed neuropil occurs by diffusion rather than bulk flow.

Shows: EM-derived neuropil simulations predict inadequate permeability for substantial physiological bulk flow.

Does not show: Model geometry and boundary assumptions remain; compatible with perivascular advection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[22] The Effect of Body Posture on Brain Glymphatic Transport.

Shows: Posture changes tracer transport and amyloid clearance in anesthetized rodents.

Does not show: Does not establish a human sleep-position prescription or natural-sleep mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[23] Circadian control of brain glymphatic and lymphatic fluid flow.

Shows: AQP4 loss eliminates circadian differences in CSF distribution and nodal drainage.

Does not show: Circadian timing and sleep are distinct; compartment redistribution is not universal net clearance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[24] Glymphatic clearance controls state-dependent changes in brain lactate concentration.

Shows: Multiple manipulations alter sleep-related lactate decline and cervical lymph-node lactate.

Does not show: Production/metabolism and pleiotropic CSF manipulations constrain selective transport attribution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[25] Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains.

Shows: Postmortem AQP4 localization relates to pathology and premortem cognition.

Does not show: Terminal tissue cannot establish direction, rate limitation or prevention by selective restoration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[26] β-Amyloid accumulation in the human brain after one night of sleep deprivation.

Shows: One-night sleep deprivation increases regional amyloid PET signal in healthy adults.

Does not show: PET change does not distinguish production from clearance or establish clinical degeneration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[27] Association Between Slow-Wave Sleep Loss and Incident Dementia.

Shows: Longitudinal slow-wave-sleep loss predicts incident dementia in Framingham.

Does not show: No selective glymphatic mediator test; prodromal disease and shared causes remain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[28] Reduced coupling between cerebrospinal fluid flow and global brain activity is linked to Alzheimer disease-related pathology.

Shows: ADNI gBOLD-CSF coupling associates with amyloid pathology and subsequent cognitive change.

Does not show: Coupling is an indirect proxy and shared neurovascular disease may produce both associations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[29] Autonomic arousals contribute to brain fluid pulsations during sleep.

Shows: Autonomic vascular regulation generates CSF pulsations without requiring slow waves or sleep.

Does not show: Pulsations do not directly measure solute clearance; weakens sleep-exclusive attribution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[30] Human NREM Sleep Promotes Brain-Wide Vasomotor and Respiratory Pulsations.

Shows: Human NREM sleep enhances vasomotor and respiratory pulsation signals.

Does not show: Physiological oscillation is not a measured clearance rate or disease endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[31] Sleep-related and diurnal effects on brain diffusivity and cerebrospinal fluid flow.

Shows: Overnight diffusivity relates to REM/circadian timing; CSF flow change is unrelated to measured sleep variables.

Does not show: Water compartmentalization and diurnal signals are not specific net solute export.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[32] Altered glymphatic enhancement of cerebrospinal fluid tracer in individuals with chronic poor sleep quality.

Shows: Poor sleep quality associates with altered contrast enrichment in non-dementia and iNPH cohorts.

Does not show: Subjective sleep, clinical selection and tracer distribution do not identify a causal pathway.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[33] Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.

Shows: Amyloid deposition and age alter CSF amyloid diurnal patterns.

Does not show: Concentrations combine release, production, transport and sequestration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[34] Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.

Shows: Amyloid diurnal patterns relate to both production and turnover.

Does not show: Kinetic association is not a selective glymphatic intervention and overlaps related clinical research.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[35] Sex-specific age-related differences in cerebrospinal fluid clearance assessed by resting-state functional magnetic resonance imaging.

Shows: gBOLD-CSF coupling declines with age and differs by sex.

Does not show: Proxy specificity and menopause interpretation are unresolved; linked prior version is not an independent study.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Update of: PMID 37034667. Subclaims: SC2, SC3.

[36] Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease.

Shows: Postmortem enlarged perivascular spaces and AQP4 differ across AD and mixed dementia.

Does not show: Regional pathology association does not establish clearance mediation or temporal primacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[37] Genome-wide association study unravels mechanisms of brain glymphatic activity.

Shows: ALPS-index GWAS finds replicated loci and overlap with ventricular/CSF-tau traits.

Does not show: Genetics of an indirect diffusion proxy is not a validated causal instrument for glymphatic neuroprotection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[38] Role of aquaporin-4 polarization in extracellular solute clearance.

Shows: Aqp4 knockout reduces solute clearance; Snta1 effect is size-specific and large-dextran clearance increases with adult age.

Does not show: Contradicts a uniform age decline and universal polarization effect; species, solute and measurement matter.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[39] AQP4-dependent enhancement of glymphatic function attenuates tau pathology and neurodegeneration in PS19 mice.

Shows: TGN-073 improves tracer influx and tau/neuron/glial endpoints in PS19; benefit is absent without AQP4.

Does not show: Genotype epistasis supports a restricted causal contribution but does not isolate every AQP4 function or human aging.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[40] Selective removal of astrocytic PERK protects against glymphatic impairment and decreases toxic aggregation of β-amyloid and tau.

Shows: Astrocytic PERK deletion/inhibition restores AQP4 localization and improves pathology/cognition in transgenic models.

Does not show: PERK affects protein synthesis and stress responses beyond clearance; model disease differs from spontaneous human degeneration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[41] Non-invasive modulation of meningeal lymphatics ameliorates ageing and Alzheimer's disease-associated pathology and cognition in mice.

Shows: Near-infrared lymphatic modulation improves cognition and pathology in aged and AD-model mice.

Does not show: Targets parallel meningeal drainage and endothelial metabolism; does not isolate sleep-dependent parenchymal convection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[42] Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice.

Shows: Cervical lymphatic ligation aggravates pathology and cognition in APP/PS1 mice.

Does not show: Surgical obstruction affects lymphatic and immune pathways; not selective glymphatic age-failure evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[43] Deletion of aquaporin-4 aggravates brain pathology after blocking of the meningeal lymphatic drainage.

Shows: Combined lymphatic blockage/AQP4 deletion worsens pathological and behavioral endpoints.

Does not show: Protein production/degradation and brain-water effects change alongside drainage.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[44] The impact of astrocytic NF-κB on healthy and Alzheimer's disease brains.

Shows: Astrocytic NF-kB has neurotoxic effects in healthy brains but inhibition worsens AD-model protein accumulation.

Does not show: Context reversal and broad inflammatory/proteomic effects challenge simple pathway enhancement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[45] Influence of an AQP4 haplotype and sleep duration on early Alzheimer's disease.

Shows: AQP4 haplotype has no overall amyloid/tau association, with age- and sleep-stratified tau signals.

Does not show: Exploratory subgroup effects and self-reported sleep are not a selective causal instrument.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[46] Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders.

Shows: Plasma biomarkers associate with modeled drainage measures in disease-specific ways and are unaffected by subjective sleep quality.

Does not show: Proxy kinetics and disease selection do not prove the same route for every biomarker.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[47] Aquaporin 4 deficiency eliminates the beneficial effects of voluntary exercise in a mouse model of Alzheimer's disease.

Shows: Early but not later exercise benefits APP/PS1 mice; AQP4 loss removes benefits.

Does not show: Timing boundary, exercise pleiotropy, germline knockout and unexamined linked erratum limit mechanistic specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 37905872. Subclaims: SC1, SC3.

[48] Direct Measurement of Cerebrospinal Fluid Production in Mice.

Shows: Anesthesia increases directly measured CSF production; aging and amyloid models reduce it.

Does not show: Production and glymphatic transport are not directly linked; ventricular blockage is invasive.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[49] Removal of aquaporin-4 from glial and ependymal membranes causes brain water accumulation.

Shows: Global AQP4 loss increases brain water, unlike selective endfoot or ependymal removal.

Does not show: Global knockout has water-homeostasis consequences beyond the proposed clearance route.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[50] PDGF-B Is Required for Development of the Glymphatic System.

Shows: PDGF-B deficiency impairs development and adult persistence of perivascular transport.

Does not show: Developmental vascular/endfoot alterations are not selective adult glymphatic perturbation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[51] Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system.

Shows: Sleep deprivation/cisternotomy changes TBI biomarker delivery to blood.

Does not show: Brain-to-blood concentrations need not index injury severity independently of drainage; restricted acute injury context.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[52] Cerebrospinal fluid influx drives acute ischemic tissue swelling.

Shows: CSF influx contributes to acute postischemic swelling.

Does not show: More influx can contribute to harmful edema; it is not universally protective clearance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[53] Very Low-Intensity Ultrasound Facilitates Glymphatic Influx and Clearance via Modulation of the TRPV4-AQP4 Pathway.

Shows: Low-intensity ultrasound increases tracer influx and injected amyloid clearance with TRPV4/AQP4-related signaling.

Does not show: Exogenous solute and pleiotropic stimulation lack a durable neurodegeneration endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[54] Impaired Macroscopic Cerebrospinal Fluid Flow by Sevoflurane in Humans during and after Anesthesia.

Shows: Sevoflurane reduces macroscopic CSF pulsations/coupling during and after anesthesia.

Does not show: Human anesthesia is not physiological sleep; clinical cognitive effects remain untested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[55] Modulation of glymphatic system by visual circuit activation alleviates memory impairment and apathy in a mouse model of Alzheimer's disease.

Shows: Visual-circuit stimulation improves model memory, AQP4 polarity and drainage, with antibody combination benefit.

Does not show: Multiple circuit/metabolic effects and transgenic pathology prevent selective human mediation inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[56] 40 Hz light flickering facilitates the glymphatic flow via adenosine signaling in mice.

Shows: Flicker enhances flow through adenosine-pathway controls independently of sleep/anesthesia.

Does not show: Enhancement does not require sleep; linked correction details are not fully audited; no human disease endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 41253750. Subclaims: SC1, SC2.

[57] Melatonin Mitigates Sleep Restriction-Induced Cognitive and Glymphatic Dysfunction Via Aquaporin-4 Polarization.

Shows: Melatonin improves sleep-restriction model cognition and transport; benefits largely disappear in AQP4-null mice.

Does not show: Hormone and sleep manipulation are pleiotropic, and model deprivation is not ordinary human aging.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[58] Sleep deprivation accelerates Parkinson's disease pathology by upregulating LAG3 in astrocytes and disrupting glymphatic system function.

Shows: Astrocytic LAG3 knockdown improves transport and pathology in sleep-deprived Parkinson models.

Does not show: PFF uptake and cell reactivity change with the intervention; artificial seeding constrains human inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[59] Chronic intermittent hypoxia impairs glymphatic function in male mice through ENT-dependent adenosine dysregulation.

Shows: Hypoxia has acute positive and chronic negative transport effects; ENT interventions rescue chronic deficits.

Does not show: Exposure duration, sex and adenosine/vascular pleiotropy prevent a universal sleep-clearance inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[60] A "glympse" into neurodegeneration: Diffusion MRI and cerebrospinal fluid aquaporin-4 for the assessment of glymphatic system in Alzheimer's disease and other dementias.

Shows: Diffusion proxies and CSF AQP4 differ across dementia stages.

Does not show: Authors identify disease-stage/structural-damage dependence; indirect markers alone cannot measure causal clearance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 39351889. Subclaims: SC1, SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• glymphatic-clearance.review.md
• glymphatic-clearance.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 60 · load-bearing claims: 64 · verified: 64 · unverified: 0 · contradicted: 0 · schema 5.3